HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy of a lipid-based barrier repair formulation in moderate-to-severe pediatric atopic dermatitis.

AbstractOBJECTIVES:
The authors assessed the efficacy of a ceramide-dominant, triple-lipid barrier repair formulation (EpiCeram), which designed to correct the lipid-biochemical abnormalities in atopic dermatitis (AD) in comparison to fluticasone propionate cream.
METHODS:
In a five-center, investigator-blinded, randomized trial, EpiCeram was compared to fluticasone (Cutivate) cream in 121 patients with moderate-to-severe AD. Primary outcome measures were: 1) reduction in disease severity, assessed as SCORAD (Severity Scoring for Atopic Dermatitis) scores; 2) improvement in pruritus; and 3) improvements in sleep habits.
RESULTS:
EpiCeram reduced clinical disease severity, decreased pruritus and improved sleep habits both 14 and 28 days after initiation of therapy. Although the fluticasone-treated group showed significantly greater improvement at 14 days, SCORAD, pruritus and sleep habit scores for EpiCeram did not differ significantly from the fluticasone-treated group by 28 days.
CONCLUSION:
The ceramide-dominant, physiological-lipid based formulation could represent an effective stand-alone or ancillary therapy for many pediatric patients with AD.
AuthorsJeffrey L Sugarman, Lawrence Charles Parish
JournalJournal of drugs in dermatology : JDD (J Drugs Dermatol) Vol. 8 Issue 12 Pg. 1106-11 (Dec 2009) ISSN: 1545-9616 [Print] United States
PMID20027938 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Androstadienes
  • Ceramides
  • Fatty Acids, Nonesterified
  • Cholesterol
  • Fluticasone
Topics
  • Adolescent
  • Androstadienes (adverse effects, therapeutic use)
  • Ceramides (administration & dosage)
  • Child
  • Child, Preschool
  • Cholesterol (administration & dosage)
  • Dermatitis, Atopic (drug therapy)
  • Fatty Acids, Nonesterified (administration & dosage)
  • Female
  • Fluticasone
  • Humans
  • Infant
  • Male
  • Single-Blind Method

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: